• Publications
  • Influence
Infliximab, azathioprine, or combination therapy for Crohn's disease.
TLDR
Patients with moderate-to-severe Crohn's disease who were treated with infliximab plus azathioprine or inflIXimab monotherapy were more likely to have a corticosteroid-free clinical remission than those receiving azATHioprine monotherapy. Expand
Infliximab for induction and maintenance therapy for ulcerative colitis.
TLDR
Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo. Expand
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management.
TLDR
It is most important to distinguish patients with severe ulcerative colitis necessitating hospital admission from those with mild or moderately active disease who can generally be managed as outpatients, and to confirm the presence of active colitis by sigmoidoscopy before starting treatment. Expand
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis.
TLDR
The aim of the Consensus is to promote a European perspective on the management of ulcerative colitis and its dilemmas to avoid duplication of effort in the future. Expand
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations.
TLDR
The aim of this Consensus was therefore critically to evaluate the optimal strategies for the management of post-operative recurrence in CD. Expand
Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.
The treatment of inflammatory bowel disease (IBD) has been revolutionised over the past decade by the increasing use of immunomodulators, mainly azathioprine (AZA)/6-mercaptopurine (6-MP) andExpand
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
TLDR
Golimumab (50 mg or 100 mg) maintained clinical response through week 54 in patients who responded to induction therapy with golimumab and had moderate-to-severe active ulcerative colitis; patients who received 100 mg Golimumab had clinical remission and mucosal healing at weeks 30 and 54. Expand
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.
TLDR
This research highlights the need to understand more fully the role of microbiota in the development of Crohn's and Colitis and the role that language plays in the management of these conditions. Expand
Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial.
TLDR
Fecal microbiota transplantation induces remission in a significantly greater percentage of patients with active UC than placebo, with no difference in adverse events. Expand
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
TLDR
ADA160/80 was safe and effective for induction of clinical remission in patients with moderately to severely active ulcerative colitis failing treatment with corticosteroids and/or immunosuppressants. Expand
...
1
2
3
4
5
...